FY2024 Earnings Forecast for ABVX Issued By Leerink Partnrs

ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) - Analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for ABIVAX Société Anonyme in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($3.08) for the year, down from their prior estimate of ($2.93). The consensus estimate for ABIVAX Société Anonyme's current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme's FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($1.09) EPS and FY2028 earnings at ($0.84) EPS.

Other equities analysts have also issued reports about the stock. Morgan Stanley reissued an "equal weight" rating and set a $12.00 price target on shares of ABIVAX Société Anonyme in a research report on Thursday. Citizens Jmp raised ABIVAX Société Anonyme to a "strong-buy" rating in a research report on Wednesday, December 4th. Finally, JMP Securities restated a "market outperform" rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, ABIVAX Société Anonyme has a consensus rating of "Buy" and a consensus target price of $38.00.

ABIVAX Société Anonyme Stock Down 0.1 %

ABIVAX Société Anonyme stock traded down $0.01 during trading hours on Thursday, hitting $7.37. 121,012 shares of the stock traded hands, compared to its average volume of 121,849. ABIVAX Société Anonyme has a 1 year low of $5.50 and a 1 year high of $16.63. The firm's 50 day moving average price is $6.74 and its 200-day moving average price is $8.46.

Remove Ads

Hedge Funds Weigh In On ABIVAX Société Anonyme

Institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP acquired a new stake in ABIVAX Société Anonyme in the fourth quarter valued at approximately $144,000. Stonepine Capital Management LLC acquired a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $110,000. Shay Capital LLC acquired a new position in shares of ABIVAX Société Anonyme during the 4th quarter worth about $366,000. Millennium Management LLC raised its position in shares of ABIVAX Société Anonyme by 44.2% during the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company's stock worth $6,816,000 after purchasing an additional 285,542 shares during the last quarter. Finally, Citadel Advisors LLC boosted its holdings in ABIVAX Société Anonyme by 83.5% in the 4th quarter. Citadel Advisors LLC now owns 855,676 shares of the company's stock worth $6,264,000 after buying an additional 389,247 shares during the last quarter. Hedge funds and other institutional investors own 47.91% of the company's stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.